যুক্তরাজ্য -
ইংরেজি -
MHRA (Medicines & Healthcare Products Regulatory Agency)
carbocisteine 375mg capsules
milpharm ltd - carbocisteine - oral capsule - 375mg
যুক্তরাজ্য -
ইংরেজি -
MHRA (Medicines & Healthcare Products Regulatory Agency)
carbocisteine 375mg capsules
viatris uk healthcare ltd - carbocisteine - oral capsule - 375mg
যুক্তরাজ্য -
ইংরেজি -
MHRA (Medicines & Healthcare Products Regulatory Agency)
carbocisteine 375mg capsules
flamingo pharma (uk) ltd - carbocisteine - oral capsule - 375mg
আয়ার্লণ্ড -
ইংরেজি -
HPRA (Health Products Regulatory Authority)
carbocisteine teva 375 milligram capsules hard
teva uk limited - carbocisteine - capsules hard - 375 milligram
যুক্তরাজ্য -
ইংরেজি -
MHRA (Medicines & Healthcare Products Regulatory Agency)
carbocisteine 750mg/10ml oral solution 10ml sachets sugar free
esteve pharmaceuticals ltd - carbocisteine - oral solution - 75mg/1ml
আয়ার্লণ্ড -
ইংরেজি -
HPRA (Health Products Regulatory Authority)
mucodyne 375 milligram capsules hard
sanofi-aventis ireland limited t/a sanofi - carbocisteine - capsules hard - 375 milligram - mucolytics
আয়ার্লণ্ড -
ইংরেজি -
HPRA (Health Products Regulatory Authority)
mucodyne 250 mg/5ml syrup
sanofi-aventis ireland limited t/a sanofi - carbocisteine - syrup - 250 mg/5ml - mucolytics
আয়ার্লণ্ড -
ইংরেজি -
HPRA (Health Products Regulatory Authority)
mucodyne paediatric syrup 125 mg/5ml syrup
sanofi-aventis ireland limited t/a sanofi - carbocisteine - syrup - 125 mg/5ml - mucolytics
যুক্তরাজ্য -
ইংরেজি -
myHealthbox
carbocisteine unither pharmaceuticals 750mg/10ml sugar-free oral solution in sachet
intrapharm laboratories limited - carbocisteine - oral solution in sachet - 750mg/10m - mucolytic - it is indicated in adults and children over 15 years for recent respiratory disorder with expectoration difficulties (difficulty rejecting by spitting out sputum).
ইউরোপীয় ইউনিয়ন -
ইংরেজি -
EMA (European Medicines Agency)
victrelis
merck sharp dohme ltd - boceprevir - hepatitis c, chronic - antivirals for systemic use - victrelis is indicated for the treatment of chronic hepatitis-c (chc) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.